Abstract: Helicobacter pylori has been implicated in the pathogenesis of a number of digestive tract disorders, such as chronic active gastritis, peptic ulceration, gastric cancer, and mucosa-associated lymphoid tissue lymphoma. Disease outcome is dependent on many factors, including bacterial genotype, host physiology and genetics, and environmental factors such as diet. Researchers continue to explore the complexities of H. pylori infection, seeking to explain why some individuals have asymptomatic infection, whereas others experience clinical disease. The importance of treating H. pylori infection in patients with gastrointestinal problems has been confirmed in recent years, with clinical trials showing that cure of infection can prevent duodenal ulcer and, to a lesser extent, gastric ulcer recurrence; cure early stage mucosa-associated lymphoid tissue lymphoma; and reduce the chances of developing gastric cancer in high-risk individuals.
D
iscovering Helicobacter pylori more than 20 years ago 1 and recognizing its association with peptic ulcer disease (PUD) were the basis for Robin Warren's and Barry Marshall's 2005 Nobel prize. H. pylori infection remains one of the world's most common bacterial infections. 2 Prevalence varies considerably throughout the world, and although exact numbers differ among sources, H. pylori infection is widespread in developing nations, where prevalence is believed to be more than 80% among middle-aged adults. 2 The prevalence of H. pylori infection in industrialized countries is considerably lower, with 20% to 50% of the population infected. 2 Subgroups in such nations including the United States and Australia, however, have a higher rate of infection than the population at large. 3 For example, older adults, blacks, and Hispanics have a considerably higher prevalence of H. pylori infection in the United States. 4 The incidence was 6 times and 3 times higher, respectively, among Hispanic immigrants and their first degree relatives, respectively, when compared with second-degree relatives 5 even after controlling for parental infection, lower level of education and crowding. Overall, an increased prevalence of H. pylori infection almost always correlates with lower educational levels, income, and other socioeconomic factors. [2] [3] [4] Infection is acquired primarily during early childhood, 2 and persists throughout life unless treated. 6 Humans seem to be the only significant carriers of H. pylori, 7, 8 and although the exact mode of transmission is uncertain, evidence suggests it can be fecal-oral, oraloral, or iatrogenic. 7, 8 There is also epidemiologic evidence that having an infected mother increases the risk of infection in a child, suggesting that transmission may occur during maternal-infant contact. [9] [10] [11] Having an infected partner is also associated with a 6-fold increase in Hp infection suggesting of the possibility of conjugal transmission. This increase among partners seems important only in countries with a H. pylori prevalence greater than 50% because no increase is seen in couples from countries with a lower prevalence. 12 Data suggest that person-to-person transmission in industrialized nations might occur via infected vomitus, saliva, or feces. 2 Though H. pylori has been cultured from saliva 13, 14 and dental plaque 15 and bacterial DNA fragments have been identified in the mouth, 13, 16 epidemiologic data to support oral-oral transmission remain weak. 13 For instance, dental workers do not have a higher incidence of H. pylori infection, 17 and couples have not shown a high concordance of infection or strain types. 18 In addition, patients who are treated do not seem to be reinfected from spouses who have not received treatment and are carrying the pathogen. 19 H. pylori infection remains the single most important cause of chronic PUD, and it has been well established that eradication therapy will heal ulcers, prevent relapses and complications, and thus cure the disease in most patients. 20 The prevalence of PUD in developed countries has been declining for several decades, a trend that began before the discovery of H. pylori and effective treatment and coincides with a reduced rate of H. pylori acquisition among the general population owing to improvements in hygiene and sanitation over the past century. 3 The widespread use of antibiotic therapy has also reduced the overall prevalence of H. pylori infection, 21 likely contributing to the downward incidence of PUD. Though prevalence rates of H. pylori infection in developing countries remain high, there is evidence that even in these countries prevalence of both H. pylori infection and PUD are declining. [22] [23] [24] Despite this decline, ulcers still lead to an estimated 1 million hospitalizations and 6500 deaths per year in the United States. 20 The annual related health care costs of PUD approach nearly $6 billion. Today, however, most of these ulcers and associated complications in the United States are unrelated to H. pylori. 25 H. pylori infection has also been recognized as the main cause of chronic gastritis and is associated with the subsequent development of gastric carcinoma (Fig. 1) . 2 Gastric cancer claims nearly a million lives throughout the world every year, and the incidence of the disease parallels the rate of H. pylori infection in most countries. 3 Although the incidence of H. pylori infection and of gastric cancer are declining in the United States and other more developed countries, 3, 26 the infection rate remains high in many parts of the world 2 and will be associated with a high degree of morbidity, mortality, and economic burden in such areas for years to come.
As the rates of known H. pylori-associated illnesses have declined in developed countries, there has been an increase in other gastrointestinal conditions 27 namely gastroesophageal reflux disease (GERD). 28 Some suggest that the rise of GERD is related to the disappearance of H. pylori 29 and question whether eradication of H. pylori is always beneficial.
This paper reviews the role of H. pylori infection in gastrointestinal diseases, including PUD [along with its relationship to nonsteroidal anti-inflammatory drug (NSAID)-associated ulcers], GERD, functional dyspepsia, gastric adenocarcinoma, and mucosa-associated lymphoid tissue (MALT) lymphoma. Although the role of H. pylori as a causative agent is clearly defined in many cases, questions remain concerning the optimal diagnostic methods and whether testing for and treating infection is always justified, economically and otherwise.
PATHOGENESIS OF H. PYLORI INFECTION
Although chronic gastritis will develop in nearly all individuals who are persistently colonized with H. pylori, 80% to 90% will never experience symptoms or develop clinical disease. 2 It has not been clearly established as to how the presence of H. pylori leads to gastric and duodenal ulcers, but disruption of gastric and duodenal mucosal integrity seems to involve a complex interaction between the host and pathogen. 7, 30 H. pylori infection elevates levels of gastrin, a gastrointestinal regulatory peptide that plays a key role in the physiologic regulation of gastric acid secretion.
31
H. pylori's effects on gastrin and acid are likely mediated through somatostatin, a peptide produced by antral D cells. Somatostatin, which serves as the ''brake'' for gastrin secretion, seems to be up-regulated or downregulated as a result of the severity and distribution of H. pylori-associated inflammation. 32 Eradication of the bacterium causes gastrin levels to return to normal. 31 An acute H. pylori infection can cause transient hypochlorhydria, 31 whereas persistent infection often leads to elevated secretion of acid, which predisposes patients to duodenal ulcers. 2 Individuals with duodenal ulcers who are also infected with H. pylori have been shown to have a high rate of gastric acid secretion, with a basal acid output that is 3 times higher than uninfected individuals. 33 These individuals with acid hypersecretion are more likely to have antral predominant gastritis, whereas those with lower acid secretion are more likely to have diffuse gastritis or inflammation predominantly confined to the body of the stomach. 2 Low acid secretion might predispose patients to gastric ulcer and, in some cases, lead to gastric carcinoma. 2 Why infection leads to antral or more diffuse gastritis in a particular individual is not known, but recent evidence suggests that host genetics and possibly bacterial characteristics play an important role.
The effects of H. pylori infection on gastric physiology are complex. The presence of H. pylori induces a chronic, active inflammation in the mucosa via the release of chemokines and cytokines (such as interleukin-8, tumor necrosis factor-a, and interleukin-1b).
2 This immune response is usually unable to eradicate the organism and instead leads to persistent gastric mucosal damage as neutrophils, lymphocytes, and plasma cells are recruited to perpetuate the inflammatory state. The organism adheres to the gastric epithelium, which disrupts membrane integrity and induces host cells to release cytotoxins, toxic proteins, platelet activating factor, and lipopolysaccharides that all further damage the gastric mucosa.
A variety of virulence factors contribute to H. pylori 's ability to cause mucosal damage. 34, 35 Virulence is primarily associated with the presence of the cag pathogenicity island (PAI), a 35 to 40-kb genomic fragment containing 29 genes. 2, 7 The PAI is present in most strains of H. pylori, although prevalence varies according to geographic location. 2, 3 The CagA protein, a known virulence marker, is encoded by the cagA gene. 7 The presence of this gene has been associated with duodenal ulceration and gastric cancer. 7 The proteins encoded by the PAI induce the production of interleukin-8 and are also involved in the translocation of CagA from the bacterium into the cytoplasm of gastric epithelial cells. 2, 7 Once it enters the host cell, CagA is phosphorylated, binds to SHP-2 tyrosine phosphatase, and affects intracellular signaling processes. 2, 7 About half of all H. pylori strains also produce the 95-kd vacuolating cytotoxin VacA, which is related to the PAI. 7 The expression of the VacA cytotoxin is associated with the presence of cagA in the PAI, 7 and although the pathogenic role of this toxin is not fully defined, it might possibly open membrane channels of gastric epithelial cells to provide the bacterium with nutrients. 2 It also targets the mitochondrial membrane, causing a release of cytochrome c and inducing apoptosis. 2 
ULCERS, NSAIDS, AND H. PYLORI
PUD is a relatively common disorder, affecting several million people in the United States every year, resulting in a high economic burden. 7 The 2 most important factors contributing to the development of ulcers are H. pylori and the use of NSAIDs. 36 Approximately, 90% of ulcers can be attributed to one or both of these factors. 36 There are sufficient data to suggest that H. pylori significantly damages the gastric and duodenal mucosa through direct pathogenic mechanisms, whereas NSAIDs indirectly promote injury through disruption of mucosal defensive mechanisms. 7, 37 Evidence suggests that NSAIDs and H. pylori infection are independently associated with PUD, 7 but the extent of any potential interaction between these factors remains controversial. NSAIDs are extremely popular and commonly used worldwide. 36 It is estimated that NSAIDs are used by more than 30 million patients on a regular basis, and during 1999 to 2000, more than 100 million prescriptions were filled in the United States, accounting for a total of nearly $5 billion in sales. An additional $1.8 billion was spent on over-the-counter NSAIDs. 36 In Western countries, use of NSAIDs is believed to be the most common cause of mucosal injury to the gastrointestinal tract, with up to half of regular users reporting some degree of gastrointestinal intolerance. 36 About a quarter of regular NSAID users are found to have endoscopically visible ulcers, and up to 4.5% go on to develop more serious gastrointestinal complications.
The influence of H. pylori infection on ulcer risk in patients receiving NSAIDs remains undefined, and studies have shown conflicting results. 36 Some studies have failed to identify a synergistic effect, whereas other trials have found that NSAID-associated injury is either increased or decreased in the presence of H. pylori. In fact, there might be circumstances where patients infected with H. pylori are actually less likely to develop NSAIDinduced ulcers than individuals who are not infected or who have undergone eradication treatment. 37 The conflicting data might be the result of differences in study design, different host response to H. pylori, study power, the choice of H. pylori diagnostic tests, previous history of ulcers or complications, NSAID-naive versus long-term users, and definitions of mucosal damage. 36, 37 In a meta-analysis addressing this issue, Huang et al 38 found that in 16 studies involving 1625 NSAID users, uncomplicated PUD was significantly more common in patients who tested positive for H. pylori versus those who tested negative (41.7% vs. 25.9%). Using data from 5 separate studies (Fig. 2) , PUD was also significantly more common in NSAID users than in a control group (35.8% vs. 8.3%), irrespective of H. pylori infection, and a synergistic effect on the risk of ulcer was seen between NSAID use and H. pylori infection. 38 Although both H. pylori infection and NSAID use raised the risk for bleeding ulcers in 6 case-control studies (odds ratio, 1.79 and 4.85, respectively), the major risk factor seemed to be NSAIDs. For patients with H. pylori infection who also took NSAIDs, the risk of a bleeding ulcer was increased even more (odds ratio, 6.13). 38 Results were mixed in a trial that specifically evaluated H. pylori as a risk factor in patients with a history of upper gastrointestinal bleeding who restarted either low-dose aspirin prophylaxis for coronary heart disease or stroke, or naproxen for arthritis after ulcer healing. 39 Eradication of the pathogen was as effective as maintenance therapy with a proton pump inhibitor (PPI) in preventing recurrent bleeding in the cohort who used only low-dose aspirin. 39 However, therapy with a PPI was superior to eradication in preventing recurrent bleeding in patients using naproxen. 39 The authors indicated it was reasonable to extend their findings to all nonaspirin NSAIDs, despite their focus on naproxen. 39 Whether H. pylori eradication benefits patients when they first begin long-term NSAID treatment is also controversial. In a controlled trial, Chan and colleagues 40 screened 210 NSAID-naive arthritis patients for H. pylori infection before beginning NSAID treatment; 61% were positive. Infected patients, all of whom had either a history of dyspepsia or ulcer, were randomized to receive antibiotic treatment or placebo before starting NSAIDs. 40 The pathogen was successfully eradicated in 90% of the antibiotic group, whereas 6% of patients in the placebo group were spontaneously cured of H. pylori infection by the end of the study period. 40 At 6 months, the probability of endoscopically visible ulcers was 12% in the eradication group, but 34% in the placebo group. 40 The probability of complicated ulcers was 4% in the eradication group and 27% in the placebo group. 40 Conversely, other data suggest that eradication of H. pylori in long-term NSAID users with past or current PUD can lead to impaired healing of gastric ulcers. In a randomized, controlled study, patients with current or previous peptic ulceration, dyspepsia, or both who were being treated with NSAIDs were randomized to receive either 1 week of PPI-based eradication (n = 142) treatment and prolonged PPI or PPI (n = 143) treatment alone until ulcers healed. 41 The patients who received eradication treatment had slower gastric-ulcer healing, and 5 developed new ulcers during the treatment period, versus only 1 in the PPI group. 41 Little difference was noted between the 2 groups in the probability of being free of ulcers at 6 months. 41 
GERD
H. pylori and GERD account for most of upper gastrointestinal problems. 42 However, the relationship between H. pylori and GERD remains unclear, and study results are conflicting. 42 Although testing for and eradication of H. pylori have become standard in the treatment of peptic ulcers, no consensus has been reached on whether this will be advantageous for patients with GERD. Some studies have found that eradication of H. pylori was linked with a higher incidence of increased acid production and subsequent reflux symptoms, whereas others found that it had no such effect. 42 Other data show that H. pylori status and eradication of infection do not affect GERD treatment outcome or likelihood that symptoms will recur. 42 Labenz et al 29 evaluated the impact of H. pylori eradication on the risk of developing reflux esophagitis in 2 different patient populations with duodenal ulcers, one of which had received antimicrobial treatment for H. pylori infection. Patients were followed up prospectively after H. pylori was eradicated (n = 244) or after diagnosis of persisting infection (n = 216), and underwent endoscopy at 1-year intervals or when upper gastrointestinal symptoms recurred. At 3 years, the incidence of reflux esophagitis as judged by life-table analysis was 25.8% in patients whose infection was eradicated and 12.9% in those with a persistent infection (Fig. 3) . Lifetable analysis suggested that infection eradication was associated with an increased risk of reflux esophagitis during the first year after treatment, but then risk became similar in both groups. 29 Patients who developed reflux esophagitis after eradication were more often men who had more severe corpus gastritis before treatment for H. pylori and who gained weight after eradication. 29 Very different results were obtained by Malfertheiner and colleagues, 43 who examined the impact of H. pylori eradication therapy on heartburn and endoscopic findings in gastric and duodenal ulcer patients. In an international trials program consisting of 5 studies, 1497 H. pylori-infected patients with a current or past gastric or duodenal ulcer were randomized to either eradication therapy or a control treatment. In all 5 studies, eradication treatment consisted of 1 week of PPI triple therapy plus antibiotics. The length of treatment varied according to the type or activity of the ulcer. 43 In all studies, the severity of heartburn was recorded at baseline and at each follow-up visit, and endoscopy was performed at baseline and from 1 to 6 months after completion of the studies. 43 In patients with a duodenal ulcer, the incidence of heartburn decreased from 32% to 12% in those with successful eradication of H. pylori. 43 In the group with persistent infection, it decreased from 39% to 25%. 43 These results suggest duodenal ulcer patients with heartburn actually benefit from H. pylori treatment. In the gastric ulcer patients, prevalence of heartburn was 51% at the beginning of the study, and at follow-up was 13% in the H. pylori-negative cohort and 14% in the H. pyloripositive cohort. 43 So although eradication of infection can improve heartburn symptoms in duodenal ulcer patients, similar improvement in gastric ulcer patients might be unrelated to the eradication of infection.
The incidence of reflux esophagitis was also evaluated at 6 months in 2 of the 5 studies. 43 Because patients with reflux disease requiring treatment were excluded from the studies, the incidence of esophagitis in this cohort was low. Four H. pylori-negative patients and 2 H. pylori-positive patients who had no erosions at baseline developed erosive esophagitis. 43 When equivocal findings, defined as minimal or imprecise changes, were also counted, there were 11 and 8 cases of esophagitis in H. pylori-positive and H. pylori-negative patients, respectively. The results showed no major impact of either failed or successful H. pylori eradication therapy on the development of erosive esophagitis. Therefore, in neither gastric nor duodenal ulcer patients does treatment of infection seem to worsen endoscopic or symptomatic GERD.
In a post hoc analysis of subjects enrolled in 8 double blind studies of H. pylori therapy, Laine and Sugg 44 found that in duodenal ulcer patients there was no increase in the prevalence or incidence of symptoms of reflux esophagitis after H. pylori treatment. In a more recent observational study, Tsukada et al 45 found that at 1 year after successful eradication of H. pylori infection, patients had higher rates of reflux esophagitis when compared with those with persistent infection; however, this relationship was reversed at 2 years. They further observed that follow-up for greater than 18 months, hiatal hernia, duodenal ulcer, and failure to eradicate H. pylori were all associated with a significant increase in reflux esophagitis. 45 Pilotto et al 46 recently published results from a clinical trial in which they randomly allocated 30 patients with esophagitis and H. pylori infection to a PPI alone and another 31 to PPI and H. pylori eradication. There was no significant difference in healing rates of esophagitis (77% vs. 77%) or symptom improvement (92.3% vs. 88.5%). However, there was a significant decrease in the prevalence of moderate or severe chronic gastritis in the H. pylori eradication group.
Any association of H. pylori with GERD is most likely related to the organism's ability to modify the acidity of gastric juice, as there is no evidence that it alters the competence of the gastroesophageal junction or esophageal acid clearance mechanisms. 28 H. pylori does cause variable patterns of gastritis, which in turn modify the composition of gastric juice, either making it more or less acidic. 28 Thus, it is likely the pattern of H. pylori gastritis and resulting level of acid secretion that ultimately determine the influence of infection and its treatment on GERD. 28 Inoue et al 47 found that successful H. pylori eradication was associated with a decrease in gastric pH (increase in gastric acidity) and a higher incidence of reflux esophagitis. In addition, virulence differences in H. pylori strains may have an impact on whether the microorganism exacerbates GERD or protects against its occurrence. 28 Geographic variability in these factors likely explains the different clinical outcomes in various study populations.
Most studies suggest that patients with duodenal ulcer are less likely to develop reflux esophagitis or to experience a worsening of symptoms after H. pylori eradication. 44, 45, [48] [49] [50] However, the following factors may 
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also be associated with an increase in the prevalence or incidence of reflux esophagitis after successful treatment of H. pylori: hiatal hernia, 47, 48 severity of corpus gastritis, 49 smoking, 50 and weight gain 50 or elevated body mass index. 48 
FUNCTIONAL DYSPEPSIA
Dyspepsia is an extremely common disorder, affecting an estimated 25% of all adults living in the United States and other Western nations. 51 Less than half of those who experience symptoms seek medical care, but dyspepsia still accounts for up to 5% of all visits to primary care practitioners. Approximately, 60% of individuals reporting symptoms have functional dyspepsia, a condition where an organic cause of upper gastrointestinal pathogenesis has been excluded. 51 There is evidence to suggest a role of H. pylori infection in functional dyspepsia, but a clear association has not been established, and the efficacy of H. pylori eradication treatment for functional dyspepsia is controversial. In one review, Chey and Moayyedi 51 reported that H. pylori eradication resulted in small but statistically significant improvements in symptoms in those with uninvestigated and investigated dyspepsia. Guidelines from the American Gastroenterological Association, and those from several European nations, recommend an H. pylori test-and-treat strategy for young patients with uncomplicated uninvestigated dyspepsia. 51 It is less expensive to test for infection than to refer a patient for endoscopy. However, in many areas of the United States, the prevalence of H. pylori in patients with dyspepsia is decreasing, and economic models suggest that a more cost-effective method of managing dyspepsia is with empiric acid suppression therapy. 51 A meta-analysis of 9 trials evaluating a total of 2541 patients with functional dyspepsia found a modest but significant benefit to H. pylori eradication treatment at 12 months. 52 The mean response rate to placebo at 1 year was 28% (range, 7% to 51%), and the mean response rate to H. pylori eradication 36% (range, 21% to 58%). According to the analysis, 1 case of dyspepsia was cured for every 15 infected patients treated. Although the eradication of H. pylori had no significant effect on quality of life and produced a rather small clinical effect, 52 the investigators felt that eradicating H. pylori might be a cost-effective intervention for functional dyspepsia. 52 
GASTRIC CANCER
Gastric cancer has a multifactorial etiology, with genetic elements, dietary factors, and H. pylori all playing a role in its development. 26 Although its incidence has slowly declined in developed countries, 26 gastric cancer remains a major global health problem. Worldwide, it is the most common malignancy of the gastrointestinal tract, and remains second only to lung cancer in cancercaused mortality. 26 The incidence of gastric cancer is predicted to continue rising in developing nations, at least for the next few decades. 26 A number of independent studies have reported a strong association between H. pylori and gastric cancer. H. pylori has been classified as a class I human carcinogen by the International Agency for Research on Cancer of the World Health Organization. 53 Gastric cancer seems to develop slowly, over the course of several decades, beginning with the acquisition of H. pylori and subsequent chronic active gastritis. 54 In fact, H. pylori sits at the beginning of a sequential paradigm of gastric carcinogenesis that has become known as Correa's cascade (Fig. 4) . [55] [56] [57] Usually initiated by H. pylori infection and perpetuated by variable environmental and host factors, 58 this model demonstrates how chronic gastritis progressively evolves to atrophic gastritis and intestinal metaplasia. [55] [56] [57] In some patients, the process will continue, and the metaplastic epithelium will undergo further genomic and phenotypic changes resulting in gastric epithelial dysplasia, and eventually, in a few, gastric cancer.
Infection with H. pylori increases the risk of cancer by 2-fold to 3-fold, and the presence of specific histologic features, such as atrophic gastritis and intestinal metaplasia, seem to be important to carcinogenesis. 58 Zhang et al 54 evaluated biopsy specimens taken from the gastric antrum, corpus, and upper angulus of 286 patients with early gastric cancer. The incidence of H. pylori infection was also evaluated in other age-matched and sex-matched control groups, consisting of patients with superficial gastritis, gastric erosion, erosive gastritis, and gastric ulcer. 54 In this study, the overall prevalence of H. pylori infection in superficial gastritis was 28.7%, erosive gastritis 57.7%, gastric erosion 63.3%, gastric ulcer 80.8%, and early gastric cancer 52.4%. 54 Of the patient population with early gastric cancer, 150 were positive for H. pylori infection and 136 were negative, but the majority in both groups displayed moderate to severe atrophic gastritis (85.5% and 84.0%, respectively). 54 Although both glandular atrophy and intestinal metaplasia were found to be higher in patients with early gastric cancer, no significant difference was noted between H. pylori-positive and H. pylori-negative patients. 54 However, the investigators suggest that based on other histologic features, even those patients with intestinal metaplasia and glandular atrophy in whom active infection could not be found had probably been infected at 1 point. 54 The progression of gastric precancerous lesions, glandular atrophy, and intestinal metaplasia in those without early gastric cancer but with superficial gastritis, gastric erosion, erosive gastritis, or gastric ulcer was strongly related to H. pylori infection. 54 Using a Helicobacter felis-infected animal model of stomach cancer, 59 investigators recently observed that gastric carcinoma might actually arise from progenitor cells of bone marrow origin that home to and engraft in an area of chronic epithelial inflammation. 59 Should these observations be confirmed, they would represent an alternative explanation for H. pylori-related carcinogenesis and have potential implications for prevention and treatment of gastric and other epithelial cancers.
In addition to H. pylori, a number of other factors have been identified that likely work together with infection to increase the risk for developing gastric cancer. 58 These include a diet high in salt and nitrates, a lack of fresh fruit and vegetable consumption, and family history.
Can eradication of infection reduce cancer risk, and if so, is there a ''point of no return'' after which antibiotic treatment no longer has any effect? Several studies address these issues.
A long-term, prospective trial in Japan by Uemura et al 60 evaluated the progression to gastric cancer in patients with H. pylori infection, using endoscopy and biopsy. Of 1526 patients who had duodenal ulcers, gastric ulcers, gastric hyperplastic polyps, or functional dyspepsia at baseline, 1246 were positive for H. pylori infection and 280 were negative. 60 The mean time of follow-up was 7.8 years (range, 1.0 to 10.6 y). 60 Patients underwent endoscopy with biopsy at the beginning of the study period and between 1 and 3 years later. 60 Gastric cancer ultimately developed in 36 of 1246 H. pylori-infected patients (2.9%), but in none of the H. pylori-negative group. 60 Gastric cancer was detected in 4.7% of patients with functional dyspepsia, 3.4% of those with gastric ulcers, and 2.2% of patients with gastric polyps. 60 None of the patients with duodenal ulcers developed gastric cancer during the study period, nor did gastric cancer develop in any of the 253 patients who underwent treatment to eradicate H. pylori infection. 60 In this study, H. pylori infection was found to be associated with the development of both intestinal-type and diffuse-type gastric cancer. 60 Is there a point of no return after which H. pylori eradication no longer prevents gastric cancer? Wong and colleagues 61 conducted a randomized, placebo-controlled H. pylori treatment trial in a Chinese population at high risk for gastric cancer. In those individuals who were treated before development of gastric atrophy or intestinal metaplasia, cancer could be prevented. 61 However, in those with atrophy or metaplasia at the time of study entry, antibiotics did not significantly reduce subsequent cancer risk. 61 This suggests that there might be a point after which eradication of infection no longer affects cancer risk, emphasizing the need to intervene as early as possible if H. pylori-associated cancer is to be averted. Despite the widespread prevalence of H. pylori infection, only a very small percentage of infected individuals ever goes on to develop gastric cancer, 60 and this might be partially owing to the presence or absence of specific genotypes of the pathogen. 3 There are multiple strains of H. pylori, and the organism is genetically diverse. 62 Several of the genotypes have been associated with virulence and clinical disease, such as the vacA type s1 strains and the vacAm1 strains. The vacAs1 strains seem to increase the risk for PUD, gastric atrophy, and gastric carcinoma, and both the vacAs1 and vacAm1 strains have been strongly linked to inflammation and epithelial damage in the gastric mucosa. CagA-positive strains are also associated with an increased risk for PUD and for the development of atrophic gastritis and gastric cancer. 62 The presence of a duodenal ulcer promoting gene (dupA) found in some strains of H. pylori seems to be ''protective'' against gastric cancer 63 although this may be an unique regional observation.
Huang et al 64 performed a meta-analysis to determine the associated risk of gastric cancer with cagA seropositivity. They identified 16 qualified studies evaluating 2284 gastric cancer patients and 2770 controls, with overall prevalence of H. pylori infection of 77.7% in patients and 63.1% in the control group. 64 In a separate analysis of 10 of the studies, cagA seropositivity was determined irrespective of H. pylori status. Almost twothirds of H. pylori strains were positive for cagA (62.8%) in the cancer patients versus 37.5% in the controls. The authors calculated that H. pylori and cagA seropositivity significantly increased the risk for gastriccancer, yielding odds ratios of 2.28 and 2.87, respectively. 64 In addition to the bacterial virulence factors, host genetic factors also seem to be relevant in increasing the susceptibility to cancer. A key factor in the pathogenesis of H. pylori is its ability to produce an inflammatory response. 65 The proinflammatory cytokine interleukin-1b (IL-1b) is up-regulated in the presence of H. pylori and plays a central role in initiating and amplifying the inflammatory response to this infection. 65 It is also a potent inhibitor of gastric acid secretion. El-Omar 65 looked at the correlation of different polymorphic expressions of the IL-1B and IL-1RN genes with hypochlorhydria and gastric atrophy in relatives of gastric cancer patients, as this type of cancer has strong familial association. They found that specific IL-1b polymorphisms significantly increase the risk of precancerous conditions.
The association between the same IL-1b genetic polymorphisms and gastric cancer was then examined in a second case-control study involving 366 gastric cancer patients and 429 population controls 65 The presence of 2 specific IL-1b gene expressions significantly increased the risk of precancerous histologic findings. In a logistic regression model including both genotypes, the estimated odds ratios associated with precancerous histology and low acid secretion for IL-1B À 511/ À 31T+ and IL-1RN*2/*2 were 1.6 and 2.9, respectively.
A follow-up population-based case-control study assessed polymorphisms of the IL-1 gene cluster and 4 other cytokine genes in patients with a variety of upper gastrointestinal cancers, including gastric cardia and noncardia adenocarcinoma, esophageal squamous cell carcinoma, and esophageal adenocarcinoma. 66 Proinflammatory genotypes of tumor necrosis factor-a and IL-10 were found to be associated with an increased risk of noncardia gastric cancer. 66 The polymorphisms, however, were not consistently related to an increased risk of either esophageal or gastric cardia cancers. The investigators also observed that the IL-1b-511T polymorphism significantly increased the risk of noncardia gastric cancer. 66 The IL-1RN*2/*2 polymorphism was associated with an increased risk of esophageal squamous cell carcinoma and noncardia gastric cancer. 66 Figueiredo et al 62 investigated combinations of bacterial and host genotypes that might be particularly associated with the occurrence of gastric carcinoma in 443 patients; 221 with chronic gastritis, and 222 with gastric carcinoma. In patients with gastritis, H. pylori vacAs1-, vacAm1-and cagA-positive bacterial genotypes were each associated with higher combined inflammatory scores in the corpus and antrum. 62 In patients with gastric carcinoma, infection with multiple vacAs or vacAm strains was more prevalent (72% and 42%, respectively) than in patients with nonatrophic gastritis (35% and 26%, respectively). 62 Patients with gastric cancer were also more likely to be infected with cagApositive strains of H. pylori (91%), compared with those with nonatrophic gastritis (40%). 62 A high proportion of gastric carcinoma patients were carriers of IL-1b À 511*T (69%), 62 and results also showed that the risk of developing gastric carcinoma was highest in patients harboring both adverse bacterial and host high-risk genotypes. 62 The greatest risk of cancer was seen in patients carrying the IL-1b À 511-511*T gene who were also infected with H. pylori of the vacAs1 genotype. This group made up 66% of the gastric carcinoma patients in the study but only 22% of individuals with nonatrophic gastritis.
Data indicate that treating H. pylori infection can improve inflammatory changes in the gastric mucosa and reduce the risk of subsequent disease. Uemura and colleagues 60 found that eradication of H. pylori seemed to halt the progression of premalignant disease, as none of the H. pylori-infected patients who received eradication therapy went on to develop cancer. However, evidence that H. pylori eradication will reverse atrophic gastritis or intestinal metaplasia and obviate subsequent gastric cancer remains inconclusive.
In a large, prospective, randomized, placebocontrolled trial, Sung et al 67 evaluated whether eradicating H. pylori would alter the course of premalignant histologic changes in the stomach. A total of 587 patients infected with H. pylori were randomly assigned to receive either a 1-week course of PPI/antibiotic therapy or placebo. 67 Both groups were comparable in their risk factors, and approximately 10% of all subjects had a family history of gastric cancer. At 1-year follow-up, an endoscopy was performed on 515 patients (treatment group: n = 261; placebo group: n = 254). In the treatment group, H. pylori infection was successfully eradicated in 226 patients. Conversely, in the placebo group, nearly all individuals remained H. pylori-positive (n = 245). 67 In both groups, pretreatment histologic inflammatory scores were comparable. 67 Most of study subjects had polymorphonuclear infiltration of the gastric mucosa in both the antrum and corpus, and more than 96% of patients also had chronic active gastritis. 67 After H. pylori eradication, the incidence of acute and chronic gastritis decreased in both the antrum and corpus, along with intestinal metaplasia in antral biopsy specimens. 67 In patients who remained infected with H. pylori, more pronounced acute gastritis was noted in antral biopsies, and an increase in acute and chronic gastritis was observed in samples from the corpus. 67 When histologic specimens from the 2 groups were compared, acute and chronic gastritis were clearly less among patients who had been cured of H. pylori infection. 67 A marginal increase in glandular atrophy was seen in patients who were still infected with H. pylori. 67 After 1 year, H. pylori eradication seemed to provide some benefit in stopping the progression of but not reversing gastric mucosal pathologic changes. 67 
MALT LYMPHOMA
Evidence exists that, in addition to being associated with gastric cancer, H. pylori is also associated with the development of MALT lymphoma, the most common gastric and possibly gastrointestinal lymphoma. 3 Gastric MALT lymphoma is a B-cell lymphoma but presumably results from chronic T-cell antigenic stimulation. It is far less prevalent than gastric adenocarcinoma, but its incidence parallels the rate of H. pylori infection in different countries. Lymphoid follicles are present in at least 30% of people with chronic, long-term H. pylori infection, 3 and while benign, these follicles are assumed to be progenitors of MALT lymphoma.
MALT lymphomas tend to progress very slowly and might manifest for a period of years as gastric ulcers that fail to completely heal, with symptoms ranging from dyspepsia to vomiting and gastrointestinal bleeding. 3 Diagnosis requires specialized immunohistologic staining of tissue to confirm that lymphoid cells are monoclonal, malignant, and of B-cell origin. Tumor staging is best done with endoscopic ultrasound. 68 An association between chronic H. pylori infection and gastric MALT lymphoma was recognized in the early 1990s, and a number of studies have confirmed this pathogenic link. 69 Accordingly, testing and treating for H. pylori infection has become an important part of tumor management. If the MALT lymphoma is at stage 1 (localized), eradication of H. pylori is now considered the accepted initial therapy. 70 Results indicate that H. pylori eradication can lead to a complete remission in approximately 80% of cases of low-grade MALT lymphoma and can sometimes even lead to remission in cases of high-grade lymphoma, as well as lymphomas of the duodenum, small intestine, rectum, and salivary glands. 69 However, H. pylori eradication as sole therapy for MALT lymphoma remains experimental, so it is recommended that other proven therapies be considered in addition to eradication especially for more advanced tumors. 3, 69, 70 Fischbach and colleagues 70 evaluated the long-term outcome of 95 patients with newly diagnosed marginal zone B-cell gastric MALT lymphoma who were treated by eradicating H. pylori. All patients had stage 1 disease and H. pylori infection and received triple therapy consisting of a PPI and antibiotics twice daily for 1 week. 70 The median follow-up time was 44.6 months (range, 12 to 89 mo). 70 H. pylori infection was successfully eradicated in 88 patients, with 2 failing therapy (5 patients were lost to follow-up). Results are presented in Figure 5 . Four patients who had gone into complete remission relapsed, 1 after being disease free for 6 months, 2 after 8 months, and 1 after 15 months. 70 One of the patients who relapsed was found to be reinfected with H. pylori and was subsequently retreated with antibiotics. With successful H. pylori eradication, this patient went back into remission.
Stolte et al 69 also reviewed the long-term results of H. pylori eradication in 120 patients with a diagnosis of MALT lymphoma. At a median follow-up period of 48 months, 81% achieved complete remission, 9% achieved partial remission, and 10% did not respond to therapy. 69 Two of the patients who failed to respond subsequently died of their lymphoma, and 9 underwent surgery. Surgical specimens revealed that 1 patient had T-cell lymphoma, 5 had secondary high-grade lymphomas, and 3 had low-grade lymphomas. Of the 97 patients who achieved complete remission after H. pylori eradication, 4 eventually died of unrelated causes. 69 Nine patients experienced a recurrence, including 1 high-grade lymphoma in the nose, and 8 low-grade recurrent lesions.
One patient with tumor recurrence was reinfected with H. pylori, and repeated eradication therapy resulted in another complete remission. Although H. pylori eradication was very effective in the treatment of low-grade MALT lymphoma, the researchers found that remission after H. pylori eradication could not be predicted based on endoscopic appearance alone.
Most MALT lymphomas that do not respond to eradication therapy are either advanced or they are associated with the t(11;18)(q21;q21) chromosomal translocation. 71 The t(11;18)(q21;q21) translocation might be the most common structural chromosomal abnormality in MALT lymphomas, occurring in about 30% of cases. 71 It results from the fusion of 2 genes, API2 and MLT, at the 11q21 and 18q21 breakpoints. The fusion of API2 and MLT seems to enhance the ability of the MALT lymphoma cells to survive.
As part of the French prospective multicenter study from the Groupe d' Etude des Lymphomes Digestifs, Liu and colleagues 71 assessed if t(11;18)(q21;q21) predicted lymphoma resistance to antibiotic therapy. Gastric MALT lymphomas regressed completely after eradication of H. pylori in 9 out of 22 patients and partially in 1 patient. 71 The remaining 12 patients were treated by other means. Eight were judged to be resistant to H. pylori eradication and 4 were tentatively assumed to be nonresponsive. None of the specimens taken from patients who responded to antibiotic therapy contained the t(11;18)(q21;q21) translocation, but 9 (75%) of the 12 patients who failed H. pylori eradication therapy had the translocation. 71 This further supports the fact that the API2-MLT fusion protein might sustain growth or survival of gastric MALT lymphoma that is independent of H. pylori. In addition, 7 of the 9 patients with translocation were found to have tumors stage IIE or higher, which suggests an association of t(11;18)(q21;q21) with a more advanced stage of the disease.
CONCLUSIONS
H. pylori continues to be one of the most common bacterial infections and much remains unknown about its pathogenesis and relationship to disorders of the gastrointestinal tract. On the basis of the extensive data, the general consensus is to treat H. pylori infection in patients with PUD and MALT lymphoma, with some recommending eradication treatment with those with precancerous changes in the gastric mucosa. However, the data relating to treatment of H. pylori in those with functional dyspepsia are more ambiguous. H. pylori's role in GERD is also less clear and the evidence for treating infection in the setting of GERD is not strong.
Owing to the wide genetic diversity of H. pylori isolates and infected hosts, it has been difficult to define the host and microbial factors that determine the ultimate clinical outcome of H. pylori infection. A large body of information concerning genetic and virulence factors is available, but the relationships are not yet sufficiently defined to guide clinicians in making treatment decisions. 
